Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.33
+0.71 (6.11%)
Mar 6, 2026, 1:01 PM EST - Market open
Entrada Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 25.42 | 210.78 | 129.01 | - | - | Upgrade
|
| Revenue Growth (YoY) | -87.94% | 63.38% | - | - | - | Upgrade
|
| Cost of Revenue | 140.57 | 125.31 | 99.88 | 66.61 | 35.93 | Upgrade
|
| Gross Profit | -115.15 | 85.48 | 29.13 | -66.61 | -35.93 | Upgrade
|
| Selling, General & Admin | 40.85 | 38.47 | 32.29 | 30.64 | 15.2 | Upgrade
|
| Operating Expenses | 40.85 | 38.47 | 32.29 | 30.64 | 15.2 | Upgrade
|
| Operating Income | -156 | 47.01 | -3.16 | -97.25 | -51.13 | Upgrade
|
| Interest & Investment Income | 15.07 | 19.47 | 15.22 | 2.63 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -140.93 | 66.49 | 12.06 | -94.62 | -51.08 | Upgrade
|
| Merger & Restructuring Charges | -1.9 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.07 | Upgrade
|
| Pretax Income | -142.83 | 66.49 | 12.06 | -94.62 | -51.16 | Upgrade
|
| Income Tax Expense | 0.92 | 0.86 | 18.74 | - | - | Upgrade
|
| Net Income | -143.75 | 65.63 | -6.69 | -94.62 | -51.16 | Upgrade
|
| Net Income to Common | -143.75 | 65.63 | -6.69 | -94.62 | -51.16 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 37 | 33 | 31 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 39 | 33 | 31 | 6 | Upgrade
|
| Shares Change (YoY) | 6.07% | 18.01% | 5.62% | 399.27% | 467.09% | Upgrade
|
| EPS (Basic) | -3.47 | 1.76 | -0.20 | -3.02 | -8.16 | Upgrade
|
| EPS (Diluted) | -3.47 | 1.68 | -0.20 | -3.02 | -8.16 | Upgrade
|
| Free Cash Flow | -129.55 | -44.72 | 134.19 | -96.67 | -55.44 | Upgrade
|
| Free Cash Flow Per Share | -3.13 | -1.15 | 4.06 | -3.09 | -8.85 | Upgrade
|
| Gross Margin | - | 40.55% | 22.58% | - | - | Upgrade
|
| Operating Margin | -613.66% | 22.30% | -2.45% | - | - | Upgrade
|
| Profit Margin | -565.48% | 31.14% | -5.18% | - | - | Upgrade
|
| Free Cash Flow Margin | -509.63% | -21.21% | 104.01% | - | - | Upgrade
|
| EBITDA | -151.9 | 50.78 | -0.32 | -95.35 | -50.01 | Upgrade
|
| EBITDA Margin | - | 24.09% | -0.25% | - | - | Upgrade
|
| D&A For EBITDA | 4.1 | 3.77 | 2.84 | 1.9 | 1.12 | Upgrade
|
| EBIT | -156 | 47.01 | -3.16 | -97.25 | -51.13 | Upgrade
|
| EBIT Margin | - | 22.30% | -2.45% | - | - | Upgrade
|
| Effective Tax Rate | - | 1.29% | 155.45% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.